AbCellera (ABCL) announced that it has entered into a settlement and patent license agreement with Bruker Corporation (BRKR), resolving the patent litigation between the two companies globally. As part of the settlement, Bruker will pay AbCellera $36M up front as well as future royalty payments on sales of Bruker’s Beacon Optofluidic platform products worldwide through the life of the licensed patents.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABCL:
- Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics
- AbCellera Appoints Dr. Stephen Quake to Board
- AbCellera Biologics’ Earnings Call: Key Insights
- 3 Best Stocks to Buy Now, 11/7/2025, According to Top Analysts
- AbCellera downgraded to Market Perform from Outperform at Leerink